
this is vyramed
we work for a better future:
Our goal is to bring knowledge, data & support to the healthcare industry. With over 50 years of combined experience in the field, we use our technical & medical expertise to bring forward impactful results.
VyraMed is a product of FetTech.
Adaptable
Can be used in conjunction with other therapies
Safe
The MTP Platform technology has been used clinically on thousands of patients with no reported adverse events
Natural
Made only of natural components
discover the unlimited potential!
our story
Early in the development of our first regenerative medicine product, we discovered that the Multi-Tissue Platform (MTP) had anti-viral activity against enveloped viruses.
During the pandemic we refocused our efforts on exploring the antiviral nature of our technology.
This has led to the development of different forms of the MTP technology, such as a powder, gel, and liquid; which all maintained the anti-viral activity.
We continue to research the anti-viral nature of the MTP technology and we’re excited to share our results and progress!
2013 - the beginning of Fettech
Danielle and Clay embarked on their journey with a vision to enhance and expand medical knowledge and innovation.
2015 - VyraMed discovery
During development of our MTP technology, we discovered it has anti-viral activity.
2019 - Pandemic begins
The COVID-19 pandemic emerged, increasing our focus and priority on development efforts for anti-viral applications.
2020 - MTP technology expanded anti-viral test data
Test results demonstrate efficacy of the MTP technology against a wide variety of enveloped viruses, including herpes, HIV, West Nile, poxviruses, coronavirus, influenza, hepatitis, rubella, and rabies.
2023 - a revolutionary breakthrough in anti-viral applications
Coming soon!